Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia

AB Foundation1 site in 1 country80 target enrollmentSeptember 2005

ConditionsCutaneous Leishmaniasis

Drugsmiltefosine antimony

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Cutaneous Leishmaniasis
Sponsor: AB Foundation
Enrollment: 80
Locations: 1
Primary Endpoint: cure rate
Status: Completed
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L braziliensis in Bolivia and cutaneous leishmaniasis due to L panamensis in Colombia. This trial is intended to evaluate miltefosine for cutaneous leishmaniasis due to L braziliensis in Bolivia. Patients will be randomly assigned to miltefosine or pentavalent antimony. Standard dose regimens will be used for both drugs.

Registry

clinicaltrials.gov

Start Date

September 2005

End Date

September 2007

Last Updated

15 years ago

Study Type

Interventional

Study Design

Parallel